Aurinia Pharmaceuticals (AUPH) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results
August 4, 2022 6:00 AM EDTNet revenue increased to $28.2 million for Q2 2022; Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS® (voclosporin) for 2022
Continued increases in LUPKYNIS Patients on Treatment; Steady Conversion Rates and Payor Coverage
EMA review of LUPKYNIS remains on track with decision expected by the end of Q3 2022
$391.7 million of cash and investments as of June 30, 2022
Conference call to be hosted today at 8:30 a.m. ET
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ:... More
